Description
Tirzepatide | 10MG
BioChain USA · Research use only
⚠
For research use only. Not for human or animal consumption. This compound is sold exclusively for in vitro research, laboratory, and analytical purposes by BioChain USA. It is not a drug, supplement, or therapeutic product of any kind.
What Is Tirzepatide?
Tirzepatide (also referenced as LY3298176) is an acylated 39-amino acid synthetic peptide engineered as a dual receptor agonist at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). In published research literature, it is frequently used to study incretin receptor signaling, glucose-dependent hormone responses, and downstream metabolic pathway dynamics.
Some publications characterize tirzepatide as an “imbalanced” or “biased” dual agonist, reflecting differences in relative potency and signaling profiles across the two receptors.
Tirzepatide in Plain Language
A non-technical overview of what tirzepatide is, what researchers have studied it for, what the evidence suggests, and what cannot be claimed about it. For research and educational purposes only.
Research-Use Disclaimer. BioChain USA sells tirzepatide strictly as a research-use-only chemical. It is not the FDA-approved pharmaceutical product Mounjaro® or Zepbound® manufactured by Eli Lilly. It is not a drug, dietary supplement, or medical product.
It is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of any condition. No statements on this page have been evaluated by the FDA.
At a glance
Tirzepatide is a lab-made peptide that activates two metabolic receptors at once, the same general family of receptors that GLP-1 medications like Ozempic target, with a second receptor added in. In research, scientists study it for how it affects appetite, blood sugar, body weight, sleep, and heart health.
A pharmaceutical version of this molecule (sold under separate brand names) is FDA-approved for several medical uses and is manufactured and distributed entirely separately from the research chemical sold here; the two are not interchangeable. The compound sold here is a research chemical, not a pharmaceutical or therapeutic product, and is not for human or animal use.
What it is
Tirzepatide is a synthetic peptide that engages two natural gut-hormone receptors at the same time: the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and the GLP-1 receptor (glucagon-like peptide-1 receptor). Researchers describe it as a dual GIP / GLP-1 receptor agonist.
Its sequence has been engineered with non-natural amino acid substitutions and a fatty-acid side chain that binds albumin in the bloodstream, published research describes these features as giving the molecule a long functional half-life suitable for long-acting receptor engagement profile in clinical research.
A pharmaceutical-grade version of this molecule is FDA-approved as the FDA-approved pharmaceutical formulation® for the treatment of type 2 diabetes (approved 2022) and as the FDA-approved pharmaceutical formulation® for chronic weight management in adults with obesity or overweight with weight-related comorbidities (approved 2023). Both are manufactured and marketed by Eli Lilly.
BioChain USA does not manufacture, distribute, or represent these pharmaceutical products. Research-grade tirzepatide is not equivalent to the FDA-approved pharmaceutical formulation® or the FDA-approved pharmaceutical formulation® in formulation, sterility, or regulatory oversight.
Research areas being investigated
- GIP receptor pharmacology research: Studied as a high-affinity agonist at the GIP receptor in cell-culture and pharmacology research.
- GLP-1 receptor pharmacology research: Examined as a GLP-1 receptor agonist with biased signaling characteristics distinct from selective GLP-1-receptor agonists.
- Glucose metabolism research: Investigated for effects on insulin secretion, glucagon suppression, and glucose-dependent insulinotropic responses.
- Body weight and food intake research: Examined in animal models for effects on food intake, energy expenditure, and adipose tissue.
- Cardiovascular and metabolic research: Studied for effects on lipid handling, hepatic fat, and blood-pressure-related endpoints in animal models.
- Peptide-engineering research: Used as an example of a multi-receptor agonist with engineered fatty-acid acylation for albumin binding and extended half-life.
What the research suggests so far
Animal / preclinical findings. In rodent and non-human primate models, tirzepatide has been described as engaging both GIP and GLP-1 receptors with distinct pharmacology, and as producing dose-dependent effects on insulin secretion, glucose handling, food intake, and body weight in published preclinical studies.
Mechanistic discussion in the literature emphasizes the additive (and in some assays synergistic) effect of combined GIP + GLP-1 agonism relative to single-receptor agonists.
Cell / lab findings. Cell-culture pharmacology has characterized tirzepatide’s receptor-binding affinities at GIPR and GLP-1R, signaling biases (cAMP versus β-arrestin recruitment), and downstream effects on insulin gene transcription and pancreatic β-cell behavior in published assay systems.
Human findings. Tirzepatide has one of the most substantial human research bases of any peptide pharmaceutical. Published Phase III investigation of this molecule has been conducted; see Source notes for bibliography.
All of those data come from a specific pharmaceutical formulation manufactured under regulated conditions and administered under medical supervision, they do not generalize to research-grade material, to non-medical use, or to populations or conditions outside the approved indications.
Limitations of the evidence. The robust clinical evidence for the FDA-approved drug product is specific to the manufactured drug under medical supervision. Research-grade material is not equivalent to a finished pharmaceutical product in formulation, sterility, dosing accuracy, or oversight.
Public-health agencies including the FDA have specifically warned about non-pharmaceutical compounded or research-grade tirzepatide products and the safety risks they pose.
Research relevance
Tirzepatide is most often discussed in research involving GIP / GLP-1 dual receptor pharmacology, insulin secretion and glucose homeostasis, food intake and body-weight regulation, hepatic and adipose lipid handling, and peptide-engineering strategies for extended half-life.
The substantial human findings come from a specific pharmaceutical product (the FDA-approved pharmaceutical formulation® / the FDA-approved pharmaceutical formulation®) administered under medical supervision; they do not, on their own, justify generalized claims about research-grade material.
What cannot be claimed about tirzepatide (research-grade material)
- It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
- It cannot be claimed to be equivalent to or a substitute for the FDA-approved pharmaceutical formulation®, the FDA-approved pharmaceutical formulation®, or any other FDA-approved pharmaceutical product.
- It cannot be claimed to treat type 2 diabetes, obesity, prediabetes, metabolic syndrome, or PCOS.
- It cannot be claimed to cause weight loss, suppress appetite, or be used for cosmetic weight management in customers.
- It cannot be claimed to be safe or effective for human or veterinary use.
- It cannot be represented as a dietary supplement.
Summary
Tirzepatide is a synthetic dual GIP / GLP-1 receptor agonist with engineered amino acid substitutions and a fatty-acid acylation that binds albumin to extend functional half-life. It is studied in research on incretin pharmacology, glucose metabolism, food intake, body weight, and peptide engineering. A pharmaceutical-grade version of the molecule is FDA-approved as the FDA-approved pharmaceutical formulation® (type 2 diabetes) and the FDA-approved pharmaceutical formulation® (chronic weight management), manufactured by Eli Lilly under regulated conditions.
Those approvals apply to the finished drug product, not to research-grade chemical material. BioChain USA’s tirzepatide is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.
Short version
Tirzepatide is a synthetic dual GIP / GLP-1 receptor agonist. It is studied in research on incretin pharmacology, glucose metabolism, food intake, and body weight. A pharmaceutical version of the molecule is FDA-approved (the FDA-approved pharmaceutical formulation® / the FDA-approved pharmaceutical formulation®); that approval does not extend to research-grade material, which is not a drug. Sold for research and laboratory use only.
Source notes
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab, 2018, foundational pharmacology / discovery report.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes ( N Engl J Med, 2021, Phase III randomized clinical trial.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity ( N Engl J Med, 2022, Phase III randomized clinical trial.
- Tirzepatide, FDA prescribing information for the FDA-approved pharmaceutical formulation® (Eli Lilly), regulatory document.
- Tirzepatide, FDA prescribing information for the FDA-approved pharmaceutical formulation® (Eli Lilly), regulatory document.
- Sinha R, et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. Expert Opin Investig Drugs / Diabetes Therapy reviews, review of pooled SURPASS / SURMOUNT data.
Source types: entry 1 is a discovery / pharmacology study; entries 2, 3 are pivotal Phase III randomized clinical trials of the FDA-approved pharmaceutical formulation; entries 4, 5 are FDA regulatory documents; entry 6 is a review article. All clinical findings refer to the FDA-approved pharmaceutical formulations the FDA-approved pharmaceutical formulation® and the FDA-approved pharmaceutical formulation®, not research-grade material.
SEO meta description
Tirzepatide (research-grade) is a synthetic dual GIP / GLP-1 receptor agonist studied in research on incretin pharmacology and metabolism. Research-use only.
Reminder. BioChain USA sells tirzepatide strictly as a research-use-only chemical for qualified laboratory and educational use. It is not the FDA-approved the FDA-approved pharmaceutical formulation® or the FDA-approved pharmaceutical formulation® drug and is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.
Chemical Reference Data
| Molecular Formula | C225H348N48O68 |
|---|---|
| Molecular Weight | ~4,813.5 g/mol |
| Peptide Length | 39 amino acids |
| Structural Classification | Acylated linear polypeptide conjugated to a C20 fatty diacid moiety via linker |
| CAS Number | 2023788-19-2 |
Structural Design and Engineering
Tirzepatide is described in published literature as a linear polypeptide built around GIP-like sequence features, with structural modifications designed to support longer persistence in biological systems. Its sequence architecture allows simultaneous engagement of both GIPR and GLP-1R.
The primary engineering feature discussed in the literature is lipidation via C20 fatty diacid conjugation, acylation through a linker attached to a lysine residue. This design is commonly discussed as a strategy to:
- Increase albumin association in biological systems
- Slow clearance and extend exposure duration in experimental models
- Reduce risk of enzymatic degradation
BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Research Applications
Tirzepatide is used as a research tool to investigate:
- Dual incretin receptor agonism, simultaneous GIPR and GLP-1R engagement and combined downstream effects
- Glucose-dependent insulin and glucagon dynamics, islet hormone response modeling under varying glucose conditions
- Signal bias and receptor selectivity, how tirzepatide’s “imbalanced” agonism produces different pathway readouts vs. selective agonists
- Appetite and gastric emptying pathways, GLP-1R- and GIP-mediated signaling themes in metabolic research models
- Lipidation and pharmacokinetic engineering, how C20 fatty diacid conjugation affects albumin binding, clearance, and receptor engagement duration
- Metabolic system modeling, glucose, lipid, and adiposity-related endpoint measurement in preclinical and clinical study contexts
Key Research Themes in the Literature
1. Dual Incretin Receptor Agonism (GIPR + GLP-1R)
Tirzepatide is widely discussed as a co-agonist that simultaneously engages both incretin receptors. Mechanistic studies examine how activation of each receptor independently and jointly contributes to:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon signaling modulation under hyperglycemic conditions
- Islet hormone dynamics (insulin, glucagon, somatostatin) across varying model conditions
The interaction between GIP and GLP-1 receptor pathways, and whether co-activation produces additive, synergistic, or distinct effects, is a recurring investigational theme in the published literature.
2. Signal Transduction and Biased Agonism
Researchers profile downstream signaling events following receptor activation, including intracellular second-messenger changes, kinase cascade activation, receptor internalization and trafficking patterns, and gene-expression marker shifts.
A prominent research topic is biased signaling, the observation that tirzepatide may produce different intracellular pathway profiles at GIPR versus GLP-1R compared with selective agonists or endogenous ligands. Some publications describe it as an “imbalanced” dual agonist, where potency and signaling output differ meaningfully between the two receptor targets.
3. Lipidation and Pharmacokinetic Engineering
The acylated structure of tirzepatide is a major theme in the peptide pharmacology literature. C20 fatty diacid conjugation is discussed as a strategy influencing:
- Albumin binding dynamics, the fatty diacid chain promotes non-covalent association with serum albumin
- Clearance and exposure duration, albumin association is described as slowing renal clearance and extending functional persistence
- Enzymatic degradation risk, structural modifications reduce susceptibility to DPP-IV and other proteolytic enzymes
4. Metabolic System Models and Clinical Research Context
Across preclinical and clinical research literature, tirzepatide is evaluated in metabolic frameworks measuring:
- Glucose-related signaling and homeostasis endpoints
- Body weight and adiposity-related outcome measures depending on study design
- Appetite signaling and food intake behavior readouts in GLP-1R- and GIP-related model systems
- Lipid and cardiometabolic endpoint measurements in clinical study contexts
BioChain USA does not present these as consumer promises. These are research literature themes and study-level observations only.
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
- COA information is batch-specific and is not interchangeable between lots.
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- For extended storage, follow standard peptide handling protocols: cold storage with protection from light and moisture.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
- If preparing solutions for laboratory use, standard guidance recommends avoiding long-term storage in reconstituted form, aliquot as appropriate for the experimental design.
BioChain USA does not provide instructions for human or animal administration.
Frequently Asked Questions
Is this product for human use?
No. Tirzepatide is not approved or intended for human or veterinary use in this context. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What is tirzepatide used for in research?
Common research applications include dual incretin receptor signaling studies (GIPR and GLP-1R), receptor bias and signal transduction profiling, metabolic pathway investigation, pharmacokinetic engineering research related to lipidation, and glucose-dependent hormone dynamics modeling. Specific applications depend on the researcher’s study design and objectives.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. Availability may vary by lot.
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.
References & additional Tirzepatide resources
Tirzepatide Overview at BioChain USA
This Tirzepatide product page lists the 10 mg lyophilized vial of the BioChain USA research-grade Tirzepatide compound.
Every Tirzepatide lot is independently third-party tested, with a COA available per batch.
Tirzepatide is supplied strictly for in vitro research use and is not approved for human or animal consumption.
Tirzepatide Product Imagery
Related BioChain Research Peptides
Tirzepatide is part of a broader catalog of research-grade peptides at BioChain USA. Each related product is third-party tested.
- GLP-RT3 research-grade peptide
- Tesamorelin research-grade peptide
- CJC-1295 + Ipamorelin research-grade peptide
- MOTS-c research-grade peptide
External Peer-Reviewed Research Literature
Investigators studying the Tirzepatide compound class may consult external research databases for published literature.
- PubMed: Tirzepatide published research literature
- NCBI PMC: Tirzepatide open access articles
- PubMed: peptide research literature
Tirzepatide FAQ
What is Tirzepatide? Tirzepatide is a research-grade compound supplied by BioChain USA as a lyophilized vial for in vitro laboratory research only.
What vial size does BioChain USA offer? This product page lists the 10 mg vial size.
Is Tirzepatide tested? Yes. Every Tirzepatide lot is independently third-party tested and ships with a COA reference when available.
Can Tirzepatide be used on humans or animals? No. Tirzepatide is supplied strictly for in vitro research use. It is not approved for human or animal consumption.
How does Tirzepatide ship? BioChain USA ships Tirzepatide as a lyophilized powder in a sealed research vial.
Where can researchers find Tirzepatide published literature? PubMed and NCBI PMC list peer-reviewed studies on the Tirzepatide compound class.
